Decoding the molecular drivers of TP53 ‐mutant acute myeloid leukaemia: Clinical implications and prognostic insights
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70271 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Lin-Ya Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Tumor Suppressor Protein p53, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Peking University Medicine Fund for world's leading discipline or discipline cluster development, Beijing Research Ward Excellence Program.
Abstract (Originalsprache)
This study aimed to investigate the distinct clinical characteristics and molecular features of TP53 ‐mutant acute myeloid leukaemia (AML) patients. We retrospectively analysed 193 TP53 ‐mutant AML patients. Better responses were observed in patients treated with the venetoclax in combination with hypomethylating agent (VEN + HMA) regimen compared to those receiving the ‘ 3 + 7 ’ regimens (composite complete remission [CRc], 53.8% vs. 30.2%; p = 0.018). TP53 V272 mutation was associated with a lower relapse rate (0% vs. 35.2%; p = 0.041). The single hit group exhibited superior OS compared to the multi‐hit group (the median overall survival [OS]: 14.3 months vs. 10.8 months; p = 0.029). TP53 ‐mutant AML patients with CEBPA bZIP in‐frame mutations showed prolonged OS (the median OS: 25.2 months vs. 13.8 months; p = 0.036). Better prognoses were also shown in patients with RUNX1‐RUNX1T1 fusion gene (the median OS: 31.1 months vs. 13.7 months; p = 0.002). Multivariate analysis identified three significant prognostic factors for OS: RUNX1‐RUNX1T1 fusion gene (hazard ratio [HR] = 0.23, 95% confidence interval [CI], 0.08–0.63; p = 0.005), RUNX1 mutation (HR = 1.84; 95% CI, 1.14–2.96; p = 0.012) and FLT3‐ITD mutation (HR = 3.14; 95% CI, 1.80–5.47; p = 0.001). In conclusion, molecular factors matter in influencing the prognosis of TP53 ‐mutant AML patients. Among them, TP53 mutation sites merit particular attention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Pe…
- Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
ORCID-Profile: Qian Jiang, Hao Jiang, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Fei-Fei Tang
Förderung
- Peking University Medicine Fund for world's leading discipline or discipline cluster development
- Beijing Research Ward Excellence Program
Zitieren
APA
Wang, L. Y., Gao, H. T., Fu, Q., Jiang, Q., Jiang, H., Wang, Y., Xu, L. P., Zhang, X. H., Huang, X. J., & Tang, F. F. (2026). Decoding the molecular drivers of TP53 ‐mutant acute myeloid leukaemia: Clinical implications and prognostic insights. British Journal of Haematology. https://doi.org/10.1111/bjh.70271
Vancouver
Wang LY, Gao HT, Fu Q, Jiang Q, Jiang H, Wang Y, et al. Decoding the molecular drivers of TP53 ‐mutant acute myeloid leukaemia: Clinical implications and prognostic insights. British Journal of Haematology. 2026. doi:10.1111/bjh.70271
BibTeX
@article{Wang2026,
author = {Wang, Lin-Ya and Gao, Hai-Tao and Fu, Qiang and Jiang, Qian and Jiang, Hao and Wang, Yu and Xu, Lan-Ping and Zhang, Xiao-Hui and Huang, Xiao-Jun and Tang, Fei-Fei},
title = {Decoding the molecular drivers of TP53 ‐mutant acute myeloid leukaemia: Clinical implications and prognostic insights},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70271}
}
EUVIMED